High Flow Nasal Cannula Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The high flow nasal cannula market size has grown rapidly in recent years. It will grow from $5.61 billion in 2024 to $6.25 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to rising disposable income, changing lifestyle trends, globalization and trade, home renovation and construction activities, e-commerce growth.

The high flow nasal cannula market size is expected to see strong growth in the next few years. It will grow to $8.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to sustainable and eco-friendly products, changing demographics, smart textiles integration, interior design trends, health and wellness textiles. Major trends in the forecast period include smart home integration, sustainable materials and practices, customization and personalization, innovative textile technologies, digital retail experiences.

The high-flow nasal cannula market is anticipated to experience growth due to the increasing incidence of asthma and COPD. Asthma, characterized by narrowed and inflamed airways with excessive mucus production, and COPD, a group of progressive lung diseases causing breathing difficulties, are contributing factors. The high-flow nasal cannula offers a potential treatment option by enhancing oxygen levels (PO2) while minimizing heart rate (HR) and respiratory rate (RR). This is particularly beneficial for severe bronchial asthma exacerbated by respiratory failure. Notably, in April 2023, Asthma + Lung UK reported a 149 percent surge in hospital admissions for children with asthma in England and Wales between 2021 and 2022, emphasizing the increasing prevalence of these respiratory conditions.

The high-flow nasal cannula market is poised for growth due to the expanding elderly population. Individuals aged 65 and older are considered part of this demographic, and the high-flow nasal cannula proves to be a safe and effective alternative for elderly patients with acute respiratory failure who may not respond to standard oxygen therapy, are intolerant of non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP), and do not meet ICU admission criteria. In November 2022, the Office for National Statistics reported a significant milestone in England and Wales, with 18.6% of the population exceeding 11 million individuals falling within the 65-and-above age group. Notably, over half a million individuals (527,900) were at least 90 years old within this segment. Hence, the growing elderly population is a key driver behind the expansion of the high-flow nasal cannula market.

Major companies in the high-flow nasal cannula market are concentrating on advanced products such as the SoftFlow High-Flow Nasal Cannula to better serve their existing customers. The SoftFlow High-Flow Nasal Cannula is a breathing assistance device that provides patients with warm, humidified, oxygen-enriched air through a nasal cannula. For example, in 2024, Fisher & Paykel Healthcare, a New Zealand-based manufacturer and marketer of products and systems for acute and chronic respiratory care, surgery, and obstructive sleep apnea treatment, introduced the Airvo 2 device as part of the Optiflow Nasal High Flow Therapy system. This device delivers heated, humidified air and oxygen at high flow rates, enhancing oxygenation and reducing the work of breathing for patients suffering from COVID-19 and other respiratory ailments. Its optimal humidity levels support mucociliary function and decrease airway dryness, thus improving patient comfort. Furthermore, the device is designed for easy setup and use, making it appropriate for various hospital environments and contributing to better clinical outcomes.

In March 2022, Quantum Leap Healthcare Collaborative (QLHC), a US-based non-profit organization committed to advancing healthcare through collaborative research and clinical trials, along with NRx Pharmaceuticals, Inc. (NRx), announced the discontinuation of the nebulized form of ZYESAMI® (Aviptadil) in the I-SPY COVID Trial. This phase 2, open-label, adaptive platform trial, registered as NCT04488081, aimed to quickly evaluate potential treatments for severely and critically ill COVID-19 patients. The decision to halt the use of ZYESAMI® was made because it did not show the expected clinical benefits. NRx, a US-based clinical-stage biopharmaceutical company, specializes in developing treatments for COVID-19 and other respiratory illnesses.

Major companies operating in the high flow nasal cannula market report are Air Liquide Medical Systems Pvt. Ltd., Becton Dickinson and Company, Koninklijke Philips N.V., Teijin Pharma Limited, ResMed Inc., Drägerwerk AG & Co. KGaA, Teleflex Incorporated, Masimo Corporation, Medical Dynamics Inc., Fisher & Paykel Healthcare Corporation Limited, Smiths Medical Inc., Vyaire Medical Inc., DeVilbiss Healthcare LLC, Armstrong Medical Ltd., Vapotherm Inc., SunMed LLC, Medin Medical Innovations GmbH, Sterimed Group, MEK-ICS Co. Ltd., Narang Medical Limited, Breas Medical AB, Bio-Med Devices Inc., Flexicare Medical Ltd., Fairmont Medical Products Pty Ltd., Besmed Health Business Corp., Löwenstein GmbH & Co. KG, Great Group Medical Co. Ltd., TNI Medical AG, Guangdong Pigeon Medical Apparatus Co.Ltd., BLS Systems Limited.

North America was the largest region in the high flow nasal cannula market in 2024. The regions covered in the high flow nasal cannula market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high-flow nasal cannula (HFNC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The high-flow nasal cannula (HFNC) market consists of sales of flow generators, oxygen blenders, nasal prongs, and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A high-flow nasal cannula (HFNC) is a medical device designed for delivering a high flow of heated and humidified oxygen-enriched air to patients with respiratory conditions. It comprises a lightweight tube connected to a machine that regulates the flow of air and oxygen. The cannula, placed in the patient's nostrils, administers a continuous stream of warm and moistened air at a higher flow rate compared to traditional oxygen therapy methods.

The primary types of high-flow nasal cannulas include air or oxygen blenders, nasal cannulas, active humidifiers, single-heated tubes, and others. Air-oxygen blenders are medical devices that blend air and oxygen to deliver a precise combination of oxygen and air to patients experiencing breathing difficulties or undergoing anesthesia. These devices find applications in various medical conditions such as acute respiratory failure, chronic obstructive pulmonary disease (COPD), carbon monoxide toxicity, bronchiectasis, sleep apnea, among others. High-flow nasal cannulas are distributed through diverse sales channels, including direct channels, and are utilized by various end-users, including hospitals and clinics, ambulatory care centers, long-term care centers, and others.

The high-flow nasal cannula market research report is one of a series of new reports that provides high-flow nasal cannula market statistics, including high-flow nasal cannula industry global market size, regional shares, competitors with a high-flow nasal cannula market share, detailed high flow nasal cannula market segments, market trends and opportunities, and any further data you may need to thrive in the high flow nasal cannula industry. This high-flow nasal cannula market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.